Biliary Tract Cancer

Common Name(s)

Biliary Tract Cancer

Bile Tract Cancer is a rare digestive cancer characterized by abnormal cell growth in the bile ducts and gallbladder. Individuals with this disorder may grow harmful tumors that can spread to the rest of the body if not diagnosed early. The bile duct system is responsible for storing and transporting bile from the liver, where it is made, to the intestines, where it helps to digest food. Incomplete development of the ducts inhibits the flow of bile. Individuals with this defect have digestion problems as well as a yellow discoloration of the eye and skin (jaundice). Doctors are usually able to diagnose this defect early in the abnormal growth process, as the resulting symptoms are quickly apparent. Treatment is developed on a case-by-case basis and depends on the specific needs of the patient. For prevention measures, digestion specialists may suggest individuals eat a lower-fat diet, or undergo surgery to relieve the blockage or create a tube to allow bile to reach the digestive system. If an individual's cancer has progressed, doctors may suggest chemotherapy to combat cancer symptoms.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Biliary Tract Cancer" returned 127 free, full-text research articles on human participants. First 3 results:

Chemotherapy and antiangiogenics in biliary tract cancer.
 

Author(s): Lipika Goyal, Dawn Q Chong, Dan G Duda, Andrew X Zhu

Journal: Lancet Oncol.. 2015 Aug;16(8):882-3.

 

Last Updated: 7 Aug 2015

Go To URL
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
 

Author(s): Juan W Valle, Harpreet Wasan, Andre Lopes, Alison C Backen, Daniel H Palmer, Karen Morris, Marian Duggan, David Cunningham, D Alan Anthoney, Pippa Corrie, Srinivasan Madhusudan, Anthony Maraveyas, Paul J Ross, Justin S Waters, Will P Steward, Charlotte Rees, Sandy Beare, Caroline Dive, John A Bridgewater

Journal: Lancet Oncol.. 2015 Aug;16(8):967-78.

 

Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed to assess the effect of the addition of cediranib (an oral inhibitor of VEGF ...

Last Updated: 7 Aug 2015

Go To URL
Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
 

Author(s): Akinori Watanabe, Mitsuhiro Kida, Shiro Miyazawa, Tomohisa Iwai, Kosuke Okuwaki, Toru Kaneko, Hiroshi Yamauchi, Miyoko Takezawa, Hiroshi Imaizumi, Wasaburo Koizumi

Journal: World J. Gastroenterol.. 2015 May;21(19):5979-84.

 

To evaluate the dose-limiting toxicities (DLTs) and determine the maximum-tolerated dose (MTD) and recommended dose (RD) of combination chemotherapy with gemcitabine, cisplatin and S-1 which is an oral fluoropyrimidine pro-drug in patients with advanced biliary tract cancer.

Last Updated: 28 May 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Biliary Tract Cancer" returned 8 free, full-text review articles on human participants. First 3 results:

Optimum chemotherapy for the management of advanced biliary tract cancer.
 

Author(s): Marwan Ghosn, Hampig Raphael Kourie, Elie El Rassy, Ralph Chebib, Fadi El Karak, Colette Hanna, Dolly Nasr

Journal: World J. Gastroenterol.. 2015 Apr;21(14):4121-5.

 

Biliary tract cancers (BTCs) are highly fatal malignancies, which are often diagnosed at an advanced stage and have relatively poor prognosis. The treatment of patients with advanced BTC is systemic, based on chemotherapy or best supportive care, depending on their performance status. ...

Last Updated: 20 Apr 2015

Go To URL
Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.
 

Author(s): Heng Liu, Qi-Di Zhang, Zheng-Hong Li, Qing-Qing Zhang, Lun-Gen Lu

Journal: World J. Gastroenterol.. 2014 Dec;20(47):18001-12.

 

To investigate the efficacy and safety of gemcitabine (Gem)-based combination chemotherapies for the treatment of advanced biliary tract cancer.

Last Updated: 30 Dec 2014

Go To URL
Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.
 

Author(s): Frédéric Fiteni, Thierry Nguyen, Dewi Vernerey, Marie-Justine Paillard, Stefano Kim, Martin Demarchi, Francine Fein, Christophe Borg, Franck Bonnetain, Xavier Pivot

Journal: Cancer Med. 2014 Dec;3(6):1502-11.

 

Cisplatin/gemcitabine association has been a standard of care for first-line regimen in advanced biliary tract cancer nevertheless oxaliplatin/gemcitabine regimen is frequently preferred. Because comparative effectiveness in clinical outcomes of cisplatin- versus oxaliplatin-containing ...

Last Updated: 5 Jan 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Second Line Therapy in Advanced Biliary Tract Cancer
 

Status: Recruiting

Condition Summary: Biliary Tract Cancer

 

Last Updated: 9 Feb 2012

Go to URL

Last Updated: 5 Feb 2016

Go to URL

Last Updated: 15 Dec 2015

Go to URL